This penny stock could double in just 2 years

This penny stock could have a revolutionary business model with the potential to transform healthcare and I think the shares could double.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

4D Pharma (LSE: DDDD) is a speculative UK penny stock that I’d like to add to my portfolio, because I think its share price could double in just two years. I’ll get why I think that, but first let’s just outline what this biotech company does.

4D Pharma is developing live biotherapeutic products (LBPs), a novel class of drug derived from the human microbiome. The microbiome is essentially microbes that live within the human body. Of particular interest for future healthcare are those in the gut. 4D Pharma has a number of drugs in phase II trials across different medical fields including immune-oncology (cancer) and gastro-intestinal (such as treatments for IBS).

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Why could this penny stock double?

Here’s the interesting part – why could the shares do phenomenally well in the coming 24 months? I expect the move into phase III trials will increase the profile of 4D Pharma with investors, both biotechnology investors and beyond.

I think the company’s US listing, on the NASDAQ exchange, will add significant liquidity and provide money for the company to keep progressing its trials. It has raised £30m and has cash on the balance sheet so future shareholders hopefully shouldn’t get diluted.

Overall though what most makes me think the share price can potentially double in two years is that by 2022, revenue is forecast to be £16.2m, from negligible revenue currently. Analyst forecasts have the shares on a price target of 405p, versus around 84p at the time of writing.

There are massive risks, however. First, there is the risk that drug trials fail, or that progress is slower than investors hope. Another concern is that there could be greater competition as the microbiome is becoming increasingly understood. Although 4D Pharma has raised money from shareholders, if trials do go on longer than expected, the company may ask backers for more money. That would dilute any holding and make it harder to make a profit.

On the balance of risk and reward, though I think 4D Pharma is a penny stock I’d likely add to my portfolio. However, it would be a small position! If things go well and it moves to making revenue, I think the share price could at least double within two years.

Another option?

I think Quarto is another penny stock with huge potential. It’s a very different company. Quarto is an illustrated book publishing and distribution company. The shares trade on a forward price-to-earnings of only seven, indicating the shares could be cheap. The group has aggressively cut debt and been adding cash to the balance sheet in recent years. That could set it up for future growth.

On the other hand, margins are quite small and revenues have been falling in consecutive years since 2017. The group also doesn’t pay a dividend, a potential red flag that management believes the group faces challenges. It could be a high-risk/high-reward penny stock that I’ll research further before deciding whether to add to my portfolio.

FREE REPORT: Why this £5 stock could be set to surge

Are you on the lookout for UK growth stocks?

If so, get this FREE no-strings report now.

While it’s available: you'll discover what we think is a top growth stock for the decade ahead.

And the performance of this company really is stunning.

In 2019, it returned £150million to shareholders through buybacks and dividends.

We believe its financial position is about as solid as anything we’ve seen.

  • Since 2016, annual revenues increased 31%
  • In March 2020, one of its senior directors LOADED UP on 25,000 shares – a position worth £90,259
  • Operating cash flow is up 47%. (Even its operating margins are rising every year!)

Quite simply, we believe it’s a fantastic Foolish growth pick.

What’s more, it deserves your attention today.

So please don’t wait another moment.

Get the full details on this £5 stock now – while your report is free.

Andy Ross owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Woman looking at a jar of pennies
Investing Articles

I think the JD Sports share price is a bargain. Here’s why

Our writer explains why the JD Sports share price has led him to buy more for his portfolio.

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is this tech stock one of the best shares to buy now?

Jabran Khan is on the hunt for the best shares to buy now for his holdings and takes a closer…

Read more »

Business development to success and FTSE 100 250 350 growth concept.
Investing Articles

3 top FTSE 250 shares to buy right now

I think the FTSE 250 is offering some great dividend and growth shares at the moment. And there are plenty…

Read more »

Happy retired couple on a yacht
Investing Articles

This growth stock has seen its shares pull back! Should I buy now?

When a growth stock sees its share price drop, I look carefully to see if I could pick up a…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

How to identify the best income shares like this one

Income shares vary in quality but this approach keeps me from making some of the worst howlers with dividend investing.

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Investing Articles

If I’d invested £1k in Tesla shares a year ago, here’s how much I’d have now

If Jon Smith had bought Tesla shares a year ago, he'd be in profit. But he has some concerns for…

Read more »

Twenty pound notes in back pocket of jeans
Investing Articles

Should I buy tobacco shares now for big dividends?

After a possible setback for electronic cigarettes, our writer explains why he would still buy tobacco shares for his income…

Read more »

a couple embrace in front of their new home
Investing Articles

3 FTSE shares I’m buying with the Help to Build scheme!

Last week, the government launched a new, Help to Build scheme. So, here are three FTSE shares that could benefit…

Read more »